Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetylsalicylic acid + caffeine + orphenadrine citrate + paracetamol
- Development stage
- Unknown
- Lead developer
- Nassington
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Paco-4 is a fixed-dose combination drug containing acetylsalicylic acid, caffeine, orphenadrine citrate, and paracetamol. It is used as a centrally acting skeletal muscle relaxant and analgesic for the symptomatic relief of painful musculoskeletal conditions, such as muscle spasms, sprains, and post-traumatic muscle pain. Within this combination, paracetamol and acetylsalicylic acid act as analgesics and antipyretics, with acetylsalicylic acid also providing anti-inflammatory effects. Orphenadrine citrate functions as a centrally acting muscle relaxant, likely through anticholinergic and NMDA receptor antagonist mechanisms. Caffeine acts as a mild central nervous system stimulant that enhances the analgesic efficacy of paracetamol and acetylsalicylic acid.
- Brand names
- Paco-4Paco4Paco 4
- Other names
- acetaminophen + aspirin + caffeine + orphenadrineacetaminophen + aspirin + caffeine + orphenadrine citrateacetylsalicylic acid + caffeine + orphenadrine + paracetamolacetylsalicylic acid + caffeine + orphenadrine citrate + paracetamolaspirin + caffeine + orphenadrine + paracetamolaspirin + caffeine + orphenadrine citrate + paracetamolparacetamol + acetylsalicylic acid + caffeine + orphenadrineparacetamol + acetylsalicylic acid + caffeine + orphenadrine citrateparacetamol + aspirin + caffeine + orphenadrineparacetamol + aspirin + caffeine + orphenadrine citrate
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on acetylsalicylic acid + caffeine + orphenadrine citrate + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetylsalicylic acid + caffeine + orphenadrine citrate + paracetamol.